N-(2-Methoxyphenyl)-3beta-O-[2,4-di-O-(alpha-L-rhamnopyranosyl)-beta-D-glucopyranosyl]-urs-12-en-28-amide

ID: ALA4467587

Chembl Id: CHEMBL4467587

PubChem CID: 155532412

Max Phase: Preclinical

Molecular Formula: C55H85NO16

Molecular Weight: 1016.28

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  COc1ccccc1NC(=O)[C@]12CC[C@@H](C)[C@H](C)[C@H]1C1=CC[C@@H]3[C@@]4(C)CC[C@H](O[C@@H]5O[C@H](CO)[C@@H](O[C@@H]6O[C@@H](C)[C@H](O)[C@@H](O)[C@H]6O)[C@H](O)[C@H]5O[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2

Standard InChI:  InChI=1S/C55H85NO16/c1-26-17-22-55(50(65)56-31-13-11-12-14-32(31)66-10)24-23-53(8)30(37(55)27(26)2)15-16-35-52(7)20-19-36(51(5,6)34(52)18-21-54(35,53)9)70-49-46(72-48-43(63)41(61)39(59)29(4)68-48)44(64)45(33(25-57)69-49)71-47-42(62)40(60)38(58)28(3)67-47/h11-15,26-29,33-49,57-64H,16-25H2,1-10H3,(H,56,65)/t26-,27+,28+,29+,33-,34+,35-,36+,37+,38+,39+,40-,41-,42-,43-,44+,45-,46-,47+,48+,49+,52+,53-,54-,55+/m1/s1

Standard InChI Key:  BFVQAVCSSYLARF-KGGJIYNHSA-N

Alternative Forms

1. Parent:

   

   ALA4467587

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 1016.28

Molecular Weight (Monoisotopic): 1015.5868

AlogP:

#Rotatable Bonds:

Polar Surface Area:

Molecular Species:

HBA:

HBD:

#RO5 Violations:

HBA (Lipinski):

HBD (Lipinski):

#RO5 Violations (Lipinski):

CX Acidic pKa:

CX Basic pKa:

CX LogP:

CX LogD:

Aromatic Rings:

Heavy Atoms:

QED Weighted:

Np Likeness Score:

References

1. Liao Y, Chen L, Li S, Cui ZN, Lei Z, Li H, Liu S, Song G..  (2019)  Structure-aided optimization of 3-O-β-chacotriosyl ursolic acid as novel H5N1 entry inhibitors with high selective index.,  27  (18): [PMID:31350154] [10.1016/j.bmc.2019.07.028]

2. Li H, Cheng C, Shi S, Wu Y, Gao Y, Liu Z, Liu M, Li Z, Huo L, Pan X, Liu S, Song G..  (2022)  Identification, optimization, and biological evaluation of 3-O-β-chacotriosyl ursolic acid derivatives as novel SARS-CoV-2 entry inhibitors by targeting the prefusion state of spike protein.,  238  [PMID:35551037] [10.1016/j.ejmech.2022.114426]

Source

Source(1):

• Scientific Literature